Every day, researchers are working to get a better understanding of celiac disease and its various presentations. Ongoing research is also exploring potential drug treatments for celiac disease.
Company to develop AMG 714 for the treatment of diet non-responsive celiac disease and refractory celiac disease (celiac disease-triggered T-cell lymphoma).
New research on a screening method could improve the celiac disease diagnosis rate in children.
Emerging therapeutic company to initially focus on addressing the significant medical and socioeconomic needs of patients with celiac disease
Although more research is needed, larazotide acetate may work better than the gluten-free diet alone in some patients.
Researcher is looking for youth (ages 12-17) who have been diagnosed with celiac disease to participate in an online study
NFCA interviews the team behind a study focused on the prevalence of celiac disease in untested family members on Madeira Island.
In addition to gluten, researchers have found that the immune system of people with celiac disease react to specific types of non-gluten protein in wheat.
NFCA talked to researchers Tricia Thompson, MS, RD and Suzanne Simpson, RD, LD to get the answers.
New research suggests ongoing stomach trouble could be due to altered microbiota
The following article appeared in the Boston Business Journal.
CONNECT WITH NFCA
Advertise with us
© 2014 National Foundation for Celiac Awareness. All rights reserved.
The information found on this website is not intended to be a replacement or substitute for professional medical treatment or for professional medical advice relative to a specific medical condition. We urge you to always seek the advice of your physician. There is no replacement for personal medical treatment and advice from your personal physician.
This site was last updated on
. If you have questions email the webmaster. celiac disease | celiac disease symptoms | gluten free products
This site complies with the HONcode standard for trustworthy health information: verify here.